Loading clinical trials...

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension

NCT02345044•Daiichi Sankyo

View on ClinicalTrials.gov

Summary

This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese hypertensive subjects. Primary endpoint is change from baseline in sitting systolic and diastolic blood pressure.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female subjects aged 20 years or older at informed consent
•Subjects with essential hypertension (Sitting SBP ≥ 140 mmHg and \< 180 mmHg, Sitting DBP ≥ 90 mmHg and \< 110 mmHg,and 24h-hr blood pressure more than 130 mmHg in SBP and 80 mmHg in DBP)

Exclusion Criteria

•Secondary hypertension or malignant hypertension
•Diabetes mellitus with albuminuria
•Serum potassium level \< 3.5 or ≥ 5.1 mEq/L
•Reversed day-night life cycle including overnight workers
•eGFR \< 60 mL/min/1.73 m\^2

Locations (1)

Osaka, Japan

Key Dates

Start Date

January 1, 2015

Primary Completion Date

August 1, 2015

Completion Date

October 1, 2015

Last Updated

October 8, 2019

Enrollment

426

ACTUAL participants

Conditions

Essential Hypertension

Interventions

CS-3150

DRUG

placebo

DRUG

eplerenone

DRUG

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

NCT06823947

Healthy Volunteers Essential Hypertension

View study

ACTIVE_NOT_RECRUITING

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

NCT06604897

Essential Hypertension

View study

COMPLETEDPHASE3

PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 8, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Inclusion Criteria

Exclusion Criteria

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Mat Pilates With Paced Breathing Versus Diaphragmatic Breathing in Stage II Hypertension

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions